Levodopa therapy and malignant melanoma
A. J. Sober and M. M. Wick
Concern has been voiced over a role for levodopa in the induction or
stimulation of growth of cutaneous malignant melanoma. Prospective query of
1,099 patients of the Melanoma Clinical Cooperative Group at the time of
presentation of their primary melanoma showed only one patient who had been
taking levodopa. It was concluded that levodopa, if a factor in the
induction of melanoma, must be playing an inconsequential role in the rapid
rise in incidence observed for this tumor over the past decade.
